Advertisement

Advertisement

BMC Cancer

Table 2 Cox regression analyses for progression-free survival and overall survival in all patients

From: Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

		Univariate			Multivariate
		Hazard ratio	(95 % CI)	P-value	Hazard ratio	(95 % CI)	P-value
Progression-free survival
EILD	Yes	1.80		0.013	1.44		0.16
	No		1.11–2.88			0.86–2.41
Age	≦56≦56	0.76		0.14	0.76		0.19
	>56		0.52–1.10			0.51–1.15
PS	0	1.41		0.089	1.49		0.073
	1,2		0.95–2.10			0.96–2.31
Comorbid disease	Yes	1.44		0.12	1.51		0.13
	No		0.91–2.28			0.88–2.58
DFI	≦2.8≦2.8	1.41		0.069	1.27		0.27
	>2.8		0.97–2.06			0.83–1.95
BMI	>25	1.64		0.036	1.22		0.47
	≦25≦25		1.03–2.59			0.71–2.07
HR (ER/PgR) status	Positive	1.49		0.062	1.25		0.37
	Negative		0.98–2.28			0.77–2.03
HER2 status	Negative	1.60		0.067	1.32		0.30
	Positive		0.97–2.65			0.77–2.26
Liver metastasis	No	0.95		0.067	0.93		0.72
	Yes		0.65–1.38			0.63–1.38
Overall survival
EILD	Yes	2.22		0.038	1.75		0.17
	No		1.05–4.71			0.78–3.91
Age	≦56≦56	0.81		0.45	0.77		0.37
	>56		0.47–1.39			0.43–1.36
PS	0	2.34		0.0021	2.37		0.0039
	1,2		1.36–4.03			1.32–4.26
Comorbid disease	Yes	0.91		0.77	1.04		0.91
	No		0.49–1.70			0.51–2.13
DFI	≦2.8≦2.8	1.78		0.038	1.53		0.18
	>2.8		1.03–3.07			0.83–2.85
BMI	>25	1.33		0.39	1.13		0.75
	≦25≦25		0.69–2.52			0.55–2.31
HR (ER/PgR) status	Positive	1.67		0.089	1.15		0.70
	Negative		0.93–3.01			0.57–2.29
HER2 status	Negative	1.87		0.093	1.42		0.39
	Positive		0.90–3.88			0.64–3.16
Liver metastasis	No	0.96		0.89	1.00		0.99
	Yes		0.56–1.64			0.56–1.79

Abbreviation: 95 % CI 95 % confidence interval, EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2

Back to article page